{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=22", "query": { "condition": "Gastric Adenocarcinomas", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 634, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T23:52:21.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07818018", "title": "A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Advanced Esophageal Cancer", "Gastric Cancer", "Advanced Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Intratumoral 2141-V11", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Fluoropyrimidine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09-04", "completion_date": "2029-09-04", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07818018" }, { "nct_id": "NCT01641939", "title": "A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Taxane", "type": "DRUG" }, { "name": "trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2012-09-03", "completion_date": "2016-04-30", "has_results": true, "last_update_posted_date": "2017-05-12", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 10, "location_summary": "Bakersfield, California • Stanford, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641939" }, { "nct_id": "NCT05052801", "title": "Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 547, "start_date": "2022-03-07", "completion_date": "2026-04-26", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 16, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Cerritos, California + 13 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052801" }, { "nct_id": "NCT05788484", "title": "A Study of CDX-585 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Head and Neck Cancer", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Bladder Urothelial Carcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Renal Cell Carcinoma", "Cholangiocarcinoma", "Pancreatic Cancer", "Other Solid Tumors" ], "interventions": [ { "name": "CDX-585", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-05-11", "completion_date": "2025-05-21", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Celebration", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05788484" }, { "nct_id": "NCT04034251", "title": "Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastric Cancer", "Esophagogastric Junction", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "BardPort Titanium Implanted Port with Peritoneal Catheter", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-06-09", "completion_date": "2024-09-05", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04034251" }, { "nct_id": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rovalpituzumab Tesirine", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2016-12-14", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 5, "location_summary": "La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03000257" }, { "nct_id": "NCT05836584", "title": "Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lymphadenectomy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-12-06", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 133, "location_summary": "Dublin, California • Fremont, California • Fresno, California + 99 more", "locations": [ { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836584" }, { "nct_id": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RO7496353", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2023-10-02", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 3, "location_summary": "Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867121" }, { "nct_id": "NCT04221893", "title": "Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IV Esophageal Adenocarcinoma", "Stage IV Esophageal Squamous Cell Carcinoma", "Stage IV Gastric Cancer", "Stage IV Adenocarcinoma of the Gastroesophageal Junction", "Stage IVA Esophageal Adenocarcinoma", "Stage IVA Esophageal Squamous Cell Carcinoma", "Stage IVA Gastric Cancer", "Stage IVA Adenocarcinoma of the Gastroesophageal Junction", "Stage IVB Esophageal Adenocarcinoma", "Stage IVB Esophageal Squamous Cell Carcinoma", "Stage IVB Gastric Cancer", "Stage IVB Gastroesophageal Junction Adenocarcinoma", "Metastatic Anal Canal Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Small Intestinal Carcinoma", "Pancreatobiliary Carcinoma", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Stage IV Anal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Radiation Therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-08-07", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 2, "location_summary": "San Francisco, California • Walnut Creek, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04221893" }, { "nct_id": "NCT06943521", "title": "A Study of MT-4561 in Patients With Various Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Cancer", "Gastric Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "Prostate Cancer", "Urothelial Carcinoma", "Neuroendocrine Tumor (NET)", "Neuroendocrine Carcinoma (NEC)", "Soft Tissue Sarcoma", "Nuclear Protein in Testis (NUT) Carcinoma" ], "interventions": [ { "name": "MT-4561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanabe Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-04-18", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-16T23:52:21.584Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943521" } ] }